Inicio・Lista de Acciones・Relay Therapeutics Inc

Relay Therapeutics Inc

Cerrado

SectorSanidad

19.73 -0.9

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

19.3

Máximo

19.95

Métricas clave
By Trading Economics
Ingresos	-10M -84M
Ventas	-2.7M 350K
BPA	-0.41
Margen de beneficios	-23,916.286
Empleados	202
EBITDA	-10M -83M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+33.67% upside

Dividendos
By Acuity
Próximas Ganancias	5 nov 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	277M 4.4B
Apertura anterior	20.63
Cierre anterior	19.73

Noticias sobre sentimiento de mercado

By Acuity

50%

163 / 340 Clasificación en Healthcare

Relay Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 ago 2026, 21:51 UTC

Social Media

Relay Therapeutics Inc is gaining in after-market trading, supported by social media discussions and a significant portfolio stake from Perceptive Advisors.

13 ago 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc is trading lower, reflecting broader declines in the biotechnology sector amid fluctuations and rising initial jobless claims.

10 ago 2026, 19:56 UTC

News

Social Media

Relay Therapeutics shares are higher after Citizens raised its price target to $26, citing confidence in the company's Phase 3 trials.

7 ago 2026, 20:06 UTC

News

Correlated Moves

Social Media

Barclays raised its price target on Relay Therapeutics to $30.00, contributing to positive sentiment amid ongoing analyst support following the company's Q2 earnings.

6 ago 2026, 23:02 UTC

News

Relay Therapeutics shares are lower in after-market hours following disappointing Q2 results, including a net loss of $83.7 million and revenue of $350,000.

5 ago 2026, 22:26 UTC

Relay Therapeutics Inc. shares advanced in after-market trading, maintaining a position above its 20-day moving average amid broader macroeconomic sentiment.

4 ago 2026, 19:26 UTC

Correlated Moves

Relay Therapeutics Inc is trading higher during Tuesday's session, continuing its upward trend since Monday's close. Broader market sentiment supports this performance.

3 ago 2026, 21:01 UTC

Relay Therapeutics Inc shares are lower in after-market trading, continuing a downward trend amid three consecutive sessions of declines and no specific news.

31 jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc shares are lower in Friday's session, reflecting broader declines in the biotech sector amid rising yields and inflation concerns.

30 jul 2026, 17:36 UTC

Correlated Moves

News

Relay Therapeutics Inc is rising as it advances its PI3Kα inhibitor for breast cancer treatment, drawing renewed interest and nearing IPO levels.

29 jul 2026, 19:36 UTC

Macro Event

Relay Therapeutics Inc shares are higher Wednesday, supported by increased trading volume and recent Federal Reserve decisions on interest rates.

28 jul 2026, 18:06 UTC

Relay Therapeutics Inc. shares are lower today amid broader market declines, influenced by significant drops in Asian indices and concerns in the semiconductor sector.

27 jul 2026, 19:56 UTC

Relay Therapeutics Inc. is trading higher, reaching a peak earlier in the session, despite no specific news driving the increase.

22 jul 2026, 15:46 UTC

Correlated Moves

Relay Therapeutics shares are lower following first-quarter results, which showed a modest decline. The Russell 2000 Index's decrease may also be influencing performance.

21 jul 2026, 21:51 UTC

Relay Therapeutics Inc shares are higher in after-market trading, reflecting strong momentum amid renewed interest in technology stocks, particularly those related to AI.

20 jul 2026, 19:16 UTC

Correlated Moves

Relay Therapeutics Inc. is trading lower amid notable volatility, reflecting broader market declines alongside a drop in the ARK Genomic Revolution ETF.

Comparación entre iguales

Cambio de precio

Relay Therapeutics Inc previsión

Precio Objetivo

By TipRanks

33.67% repunte

Estimación a 12 Meses

Media 26.64 USD 33.67%

Máximo 31 USD

Mínimo 20 USD

De acuerdo con 12 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Relay Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

12 ratings

Comprar

Mantener

Vender

De acuerdo con 12 analistas que ofrecen calificaciones bursátiles a para Relay Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

163 / 340 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Relay Therapeutics Inc

Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors. In addition, it has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of GDC-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.